Ask Warren

DongKook Pharmaceutical

086450 · KOSDAQ · ₩086450 · 동국제약

₩24,050▼ ₩300 (1.23%)End-of-day · Oct 28, 2026 · End-of-day prices.
Trade
Alert me
Price · 1Y +28.75%
Market cap
₩1.1T
Enterprise value
₩976B
P/E
14.3×
P/B
1.6×
Dividend yield
0.8%
ROE
11.0%
Net margin
7.8%

Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.

52-week range−23.0% from the high

₩16,260Today: ₩23,450 – ₩24,950₩31,250

Returns

  • 1W−2.4%
  • 1M+14.3%
  • 3M+41.1%
  • 6M−2.2%
  • YTD+40.2%
  • 1Y+28.7%
Volume today
611,012
0.9× the 20-day average
Traded today
₩15B
Listed shares
45,230,420
EPS (12 months)
₩1,687
Earnings yield 7.0%
SellBuy
AI research · Update noteDongKook Pharmaceutical: Model Fair Value Estimate Rises 69% to ₩33,780 Per ShareThe operating data is consistent with the earlier report: steady growth, stable margins and low leverage, with liabilities at 40.1% of equity.Read the full report →

Upcoming dates

Full calendar →

🎁 Gift this stock

Send a friend ₩100,000 of paper money in this stock. They get it when they join.

XfWATGr/in@

Signals

43Quiet
  • BuzzQuietBuzz 43 of 100 (50 is a normal day for this stock).
  • MomentumStrong12.6% over the last month; the price is above its 20-day average.
  • News impactLow5 news items and filings in two weeks; 0 rated high impact, 0 medium.
  • StreetSteady1 brokers, average target 33% from the price; last 30 days: 0 raised, 0 cut.

Signals describe activity, not recommendations. Not financial advice.

Leveraged ETF flows

Estimated leveraged-ETF rebalance on Oct 28: buy ₩1.9B at the close (11.9% of 20-day average trading value)

Sep 29Last 20 trading days (% of average trading value)Oct 28

On its 23 biggest days of the last 60 (moves of 3%+), the estimated pressure averaged 11.2% of trading value and pointed the same way 13 of 23 times.

  • 2× KODEX KOSDAQ150 Leverage ₩1.7B
  • -1× KODEX KOSDAQ150 Futures Inverse ₩93M
  • 2× TIGER KOSDAQ150 Leverage ₩85M
  • 2× RISE KOSDAQ150 Futures Leverage ₩16M
  • -1× TIGER KOSDAQ150 Futures Inverse ₩3.1M

Mostly via futures: index funds hedge with KOSPI 200 / KOSDAQ 150 futures, spread here over the index's largest members by market value.

Final after the close. An intraday "if the close were now" estimate needs real-time prices, which we don't have yet.

Estimate based on ETF size and daily moves; actual trades may differ.

ETFs holding this

All ETFs →

Held by 11 funds.

Estimated from the funds' index or underlying stock.

DongKook Pharmaceutical stock overview

DongKook Pharmaceutical (동국제약, KRX: 086450) is listed on KOSDAQ, in the Biotech & Pharma sector. Dongkook Pharmaceutical is a Korean company founded in 1968 that aims to become South Korea's top total healthcare group. Its shares closed at ₩24,050 on Oct 28, 2026, down 1.23% on the day, giving it a market value of ₩1.1T.

Key facts

Market cap
₩1.1T
Sector
Biotech & Pharma
Latest price change
−1.23%
As of
Oct 28, 2026
Main business
Dongkook Pharmaceutical is a Korean company founded in 1968 that aims to become South Korea's top total healthcare group.

Quick answers about DongKook Pharmaceutical

What does DongKook Pharmaceutical do?
Dongkook Pharmaceutical is a Korean company founded in 1968 that aims to become South Korea's top total healthcare group. It develops, manufactures and sells over-the-counter medicines such as Intedol for gum disease, Madecassol for wound care and Oramedi for mouth ulcers, along with prescription drugs including the contrast agent Pharmire and the anticancer drug Lupron Depot. Its health care segment offers health functional foods, dermo-cosmetics, and household and personal care products, and it exports pharmaceutical products to China, Japan, Latin America, Europe and other regions.
What is the market cap of DongKook Pharmaceutical?
The market capitalisation of DongKook Pharmaceutical was ₩1.1T at the close on Oct 28, 2026.
What is the analyst target price for DongKook Pharmaceutical?
The average target price of 1 broker covering DongKook Pharmaceutical is ₩32,000 (range ₩32,000 to ₩32,000), 33.1% above versus the latest price, based on each broker's latest public report within six months.
Who are the largest shareholders of DongKook Pharmaceutical?
According to the latest official filings, the largest reported holders are Kwon Ki-beom (43.96%, as of May 26, 2026); DK&Comm (20.62%, as of Oct 17, 2025); VIP Asset Management (4.81%, as of Oct 27, 2025).
When is the next earnings report from DongKook Pharmaceutical?
Korean companies rarely announce results dates in advance. Based on when DongKook Pharmaceutical filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
Does the National Pension Service own DongKook Pharmaceutical?
Yes. The National Pension Service held 3.33% of DongKook Pharmaceutical shares as of Dec 31, 2025.

Company profile

Dongkook Pharmaceutical is a Korean company founded in 1968 that aims to become South Korea's top total healthcare group. It develops, manufactures and sells over-the-counter medicines such as Intedol for gum disease, Madecassol for wound care and Oramedi for mouth ulcers, along with prescription drugs including the contrast agent Pharmire and the anticancer drug Lupron Depot. Its health care segment offers health functional foods, dermo-cosmetics, and household and personal care products, and it exports pharmaceutical products to China, Japan, Latin America, Europe and other regions.

Written by AI from the company's latest annual report.

Korean name
동국제약
Sector
Biotech & Pharma
Themes
Pharmaceuticals
CEO
송준호
Founded
Oct 1968
Listed
May 2007
Listed shares
45,230,420
Fiscal year ends
Month 12
Website
www.dkpharm.co.kr

Similar companies

Recent news

Recent filings

See all

Titles in Korean until English translations are added.

Also known as: DongKook Pharmaceutical / 동국제약 / 086450 / KRX:086450

Source: KRX statistical information